http://54.88.27.110/papers/abstract-p1-21-05-a-novel-long-acting-insulin-for-cancer-therapy-reduces-xenograft-tumor-growth/http://54.88.27.110/papers/disrupting-insulin-and-igf-receptor-function-in-cancer/http://54.88.27.110/papers/an-ultra-long-acting-recombinant-insulin-for-the-treatment-of-diabetes-mellitus-in-cats/http://54.88.27.110/papers/development-of-an-igg-fc-fusion-covid-19-subunit-vaccine-aks-452/http://54.88.27.110/papers/abstract-p4-02-01-targeting-insulin-receptor-in-estrogen-receptor-positive-breast-cancer/http://54.88.27.110/papers/phase-i-interim-results-of-a-phase-i-ii-study-of-the-igg-fc-fusion-covid-19-subunit-vaccine-aks-452/http://54.88.27.110/papers/ultra-long-acting-recombinant-insulin-for-the-treatment-of-diabetes-mellitus-in-dogs/http://54.88.27.110/papers/a-randomized-phase-i-ii-safety-and-immunogenicity-study-of-the-montanide-adjuvanted-sars-cov-2-spike-protein-rbd-fc-vaccine-aks-452/